RxDoctor Payments Data

Ehab Zekri

Family · Milford, MANPI 1295306280

Payments from drug & device makers

$4,348in general payments, 2019–2025

Across 152 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$646
  • Novo Nordisk$544
  • Lilly USA, LLC$450
  • Bayer$369
  • Corcept Therapeutics$301
  • Sanofi-aventis U.S. LLC$295
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,348 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide331$431,990
JardianceEmpagliflozin388$394,033
MounjaroTirzepatide193$271,195
FarxigaDapagliflozin Propanediol163$151,994
TrulicityDulaglutide54$92,285
RybelsusSemaglutide39$70,368
Tresiba Flextouch U-200Insulin Degludec54$65,431
Tresiba Flextouch U-100Insulin Degludec73$51,951
Fiasp FlextouchInsulin Aspart (Niacinamide)38$33,885
Humulin R U-500 KwikpenInsulin Regular, Human20$26,259
KerendiaFinerenone21$25,337
Humalog Kwikpen U-100Insulin Lispro76$24,155
Lantus SolostarInsulin Glargine,hum.Rec.Anlog167$23,991
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$20,925
Novolog FlexpenInsulin Aspart50$19,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$544$502,358370 claims
Boehringer IngelheimJardiance$113$394,033388 claims
Lilly USA, LLCMounjaro, Trulicity$450$363,479247 claims
AstraZenecaFarxiga$136$151,994163 claims
BayerKerendia$369$25,33721 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$45$2,312194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.

Other family in Milford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →